Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

By Eiermann W.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 57-62

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer

By Yardley Denise A.   Daniel Davey   Stipanov Michael   Drosick D. Randolph   Mainwaring Mark   Peyton James   Shastry Mythili   Hainsworth John D.  

Cancer Investigation, Vol. 28, Iss. 8, 2010-09 ,pp. : 865-871

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment

By                      

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 1887-1892

Spandidos Publications

Access to resources Recommend Favorite

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

By Miles David   Baselga José   Amadori Dino   Sunpaweravong Patrapim   Semiglazov Vladimir   Knott Adam   Clark Emma   Ross Graham   Swain Sandra  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 89-99

Springer Publishing Company

Access to resources Recommend Favorite